Investment View: Vodafone and GSK – my twin choices for an equitable return

Vodafone. Price: 170p. OUR VIEW: Buy
GlaxoSmithKline. PRICE: 1,427.5p OUR VIEW: Buy

Can equity markets remain at their current levels or is there another nasty squall bubbling on the horizon?

Well, if you put 10 professionals in a room together you would almost certainly get 10 different answers.

The main word on everyone's lips at the moment is "uncertainty". Nobody is really sure what nasties might be peeping over the horizon. And equities could easily take a bath if any of those nasties jumps up, just as one did in August last year.

The most obvious shocks are likely to come from Europe, where the next crisis in the sovereign debt of a fringe country (Spain?) looks like it is just waiting to break out. But don't forget the US, which has debt problems of its own, not helped by a bitterly partisan Congress and a presidential election. And don't forget China. On Friday, its GDP growth came in at the low end of where it has been historically. Time to bite those fingernails?

Maybe not just yet. Balanced against that, there have been at least some signs of economic improvement in places, but if things are actually getting better, people don't want to risk saying so just yet. What should sustain share prices at their current levels is monetary policy across Europe and the US. Rock-bottom interest rates mean you get nothing for holding cash. Bond yields are also pitiful, at least on those you might want to hold (eg German bunds, or perhaps gilts).

In other words, if you want any sort of return, equities are just about the only asset class that can provide it. The numbers tell their own story: the FTSE 100 currently yields just under 4 per cent, against a 10-year gilt offering just over 2 per cent.

All the same, against this background a safety-first strategy is no bad thing. Bill Dinning, the head of strategy and economics at Kames Capital, sums it up nicely: "Companies with high dividend yields and good prospects of increasing those dividends are attractive."

Here are two that I like, both of which fit the bill.

First up is Vodafone. The shares have basically been treading water for the past six months. However, they have much to recommend them. Whatever happens to the global economy people are not going to stop using their mobile phones.

Strategically Vodafone has been doing the right things. It has been cutting down on the number of small stakes it has all over the place, sensibly rationalising its portfolio. The dividend from its US joint venture is being shared out among investors. It has been very actively buying back shares in recent weeks. Then there is the impressive, and growing, dividend yield. Vodafone offers a forecast payout of 7.4 per cent for the year to the end of March 2012, 7.6 per cent for the current trading year.

The business is highly cash generative (so the yield isn't under much threat) and ought to be able to start growing earnings per share next year.

This column is unique among investment views in at least taking note of ethical issues, and Vodafone's tax affairs have been attracting a fair amount of comment recently. Let's be clear about this: if the company deserves a kicking for paying a pittance, then so does HM Revenue & Customs for allowing this. I suspect the group will ultimately have to dig into its pockets to keep everyone happy.

That needs to be borne in mind, but Vodafone still trades on a relatively benign forecast multiple of 10.8 times this year's earnings. Unlike the cigarette companies I looked at last week, Vodafone does hold a place in the FTSE4Good index, so it at least meets various corporate and social responsibility standards (take your own view on how good those standards are).

As does GlaxoSmithKline (GSK), the drugs group which is my second safety-first pick. Its yield is not quite as spectacular, forecast at 5.2 per cent for this year and 5.6 per cent next year, but earnings per share growth is better (7 per cent this year followed by 9 per cent). At the same time, its multiple is by no means stretched at 11.6 times forecast 2012 earnings, falling to 10.7 times in 2013.

GSK's product is even more resistant to a fresh downturn than Vodafone's (people don't stop getting sick in a recession, au contraire) and the company looks to be in fair health.

Drugs companies, it is true, aren't finding life easy right now. New treatments are proving hard, and expensive, to develop.

GSK does at least have the resources to gobble up any promising biotech it should want, and is taking advantage of government measures to make research cheaper from a taxation standpoint (if you develop and patent new treatments in the UK you pay tax at just 10 per cent on the earnings).

Again, GSK is a good, safety-first buy whose yield alone should keep investors happy even if share prices generally prove to be choppy.

PROMOTED VIDEO
News
ebooksNow available in paperback
Arts and Entertainment
All in a day's work: the players in the forthcoming 'Posh People: Inside Tatler'
TVGrace Dent thinks we should learn to 'hug a Hooray Henry', because poshness is an accident of birth
News
Jeremy Paxman has admitted he is a 'one-nation Tory' and complained that Newsnight is made by idealistic '13-year-olds' who foolishly think they can 'change the world'.
peopleFormer Newsnight presenter is being touted for a brand new role
News
The two-year-old said she cut off her fringe because it was getting in her eyes
news
Arts and Entertainment
Avatar grossed $2.8bn at the box office after its release in 2009
film
Sport
football
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Citifocus Ltd: German Speaking Client Specialist

£Attractive Package: Citifocus Ltd: Prestigious asset management house seeks a...

Citifocus Ltd: Performance & Risk Oversight

£Negotiable: Citifocus Ltd: This is a varied role focusing on the firm's mutua...

h2 Recruit Ltd: Sales Director - SaaS (SME/Channel) - £140,000 OTE

£90000 - £140000 per annum + benefits: h2 Recruit Ltd: Are you a high achievin...

h2 Recruit Ltd: Telesales Executive - Cloud Software/SaaS - £37,000 OTE

£25000 - £37000 per annum + benefits: h2 Recruit Ltd: Are you seeking to furth...

Day In a Page

Homeless Veterans Christmas Appeal: ‘We give them hope. They come to us when no one else can help’

Christmas Appeal

Meet the charity giving homeless veterans hope – and who they turn to when no one else can help
Should doctors and patients learn to plan humane, happier endings rather than trying to prolong life?

Is it always right to try to prolong life?

Most of us would prefer to die in our own beds, with our families beside us. But, as a GP, Margaret McCartney sees too many end their days in a medicalised battle
Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night - is that what it takes for women to get to the top?

What does it take for women to get to the top?

Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night and told women they had to do more if they wanted to get on
Christmas jumper craze: Inside the UK factory behind this year's multicultural must-have

Knitting pretty: British Christmas Jumpers

Simmy Richman visits Jack Masters, the company behind this year's multicultural must-have
French chefs have launched a campaign to end violence in kitchens - should British restaurants follow suit?

French chefs campaign against bullying

A group of top chefs signed a manifesto against violence in kitchens following the sacking of a chef at a Paris restaurant for scalding his kitchen assistant with a white-hot spoon
Radio 4 to broadcast 10-hour War and Peace on New Year's Day as Controller warns of cuts

Just what you need on a New Year hangover...

Radio 4 to broadcast 10-hour adaptation of War and Peace on first day of 2015
Cuba set to stage its first US musical in 50 years

Cuba to stage first US musical in 50 years

Claire Allfree finds out if the new production of Rent will hit the right note in Havana
Christmas 2014: 10 best educational toys

Learn and play: 10 best educational toys

Of course you want them to have fun, but even better if they can learn at the same time
Paul Scholes column: I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season

Paul Scholes column

I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season
Lewis Moody column: Stuart Lancaster has made all the right calls – now England must deliver

Lewis Moody: Lancaster has made all the right calls – now England must deliver

So what must the red-rose do differently? They have to take the points on offer 
Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

It's in all our interests to look after servicemen and women who fall on hard times, say party leaders
Millionaire Sol Campbell wades into wealthy backlash against Labour's mansion tax

Sol Campbell cries foul at Labour's mansion tax

The former England defender joins Myleene Klass, Griff Rhys Jones and Melvyn Bragg in criticising proposals
Nicolas Sarkozy returns: The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?

Sarkozy returns

The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?
Is the criticism of Ed Miliband a coded form of anti-Semitism?

Is the criticism of Miliband anti-Semitic?

Attacks on the Labour leader have coalesced around a sense that he is different, weird, a man apart. But is the criticism more sinister?
Ouija boards are the must-have gift this Christmas, fuelled by a schlock horror film

Ouija boards are the must-have festive gift

Simon Usborne explores the appeal - and mysteries - of a century-old parlour game